HomeNBIX • NASDAQ
Neurocrine Biosciences Inc
add
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 627.70M | 21.84% |
Operating expense | 301.80M | 37.87% |
Net income | 103.10M | -30.20% |
Net profit margin | 16.43 | -42.69% |
Earnings per share | 1.69 | 9.74% |
EBITDA | 138.10M | -11.47% |
Effective tax rate | 36.59% | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 1.08B | 4.31% |
Total assets | 3.72B | 14.37% |
Total liabilities | 1.13B | 10.75% |
Total equity | 2.59B | — |
Shares outstanding | 99.70M | — |
Price to book | 4.16 | — |
Return on assets | 9.03% | — |
Return on capital | 10.75% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | 103.10M | -30.20% |
Cash from operations | 242.50M | 96.36% |
Cash from investing | -68.30M | 66.15% |
Cash from financing | -290.00M | -919.21% |
Net change in cash | -116.10M | -172.54% |
Free cash flow | 220.28M | 138.04% |
Previous close
$108.31
Year range
$105.18 - $157.98
Market cap
10.80B USD
Avg Volume
1.29M
P/E ratio
32.91
Dividend yield
-
Primary exchange
NASDAQ
About
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
Founded
1992
Headquarters
Website
Employees
1,800
